Acumen Pharmaceuticals (ABOS) Non-Current Deffered Revenue (2022 - 2023)
Acumen Pharmaceuticals' (ABOS) quarterly Non-Current Deffered Revenue came in at $183000.0 in Q2 2023, down 23.11% year-over-year from $238000.0 in Q2 2022, and down 45.7% quarter-over-quarter from $337000.0 in Q3 2022.
Powered by 
Analysis
Acumen Pharmaceuticals (ABOS) Non-Current Deffered Revenue (2022 - 2023) Analysis & Trends
Acumen Pharmaceuticals has disclosed Non-Current Deffered Revenue across 2 years of filings, most recently posting $183000.0 for Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 220.40 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 147.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Acumen Pharmaceuticals | 205.91 Mn | 205.91 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 183,000.00 |
| Sep 30, 2022 | 337,000.00 |
| Jun 30, 2022 | 238,000.00 |